John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2726
Orion Group Holdings
ORN
$373M
| $159K | ﹤0.01% |
+19,448
| New | +$126K |
|
|
EU
2727
enCore Energy
EU
$268M
| $159K | ﹤0.01% |
36,351
-395,198
| -92% | -$1.67M |
|
2728
Sable Offshore Corp
SOC
$906M
| $159K | ﹤0.01% |
+14,491
| New | +$171K |
|
|
EXAI
2729
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $159K | ﹤0.01% |
27,763
-27,070
| -49% | -$168K |
|
2730
OP Bancorp
OPBK
$226M
| $159K | ﹤0.01% |
15,905
-100
| -0.6% | -$1.04K |
|
|
AIOT
2731
PowerFleet Inc
AIOT
$400M
| $158K | ﹤0.01% |
29,645
+13,545
| +84% | +$45.9K |
|
2732
InflaRx
IFRX
$336M
| $157K | ﹤0.01% |
102,215
-36,160
| -26% | -$59.1K |
|
2733
Algoma Steel
ASTL
$416M
| $157K | ﹤0.01% |
18,440
-180,640
| -91% | -$1.53M |
|
|
JOBY.WS
2734
DELISTED
Joby Aviation Warrants
JOBY.WS
| $156K | ﹤0.01% |
200,000
+86,341
| +76% | +$78.8K |
|
|
VIGL
2735
DELISTED
Vigil Neuroscience
VIGL
| $153K | ﹤0.01% |
44,998
+29,270
| +186% | +$91.4K |
|
2736
Crawford & Co Class A
CRD.A
$619M
| $153K | ﹤0.01% |
16,257
-39,700
| -71% | -$455K |
|
2737
Rigetti Computing
RGTI
$5.72B
| $153K | ﹤0.01% |
100,034
-650,691
| -87% | -$939K |
|
2738
Harte-Hanks
HHS
$29.7M
| $153K | ﹤0.01% |
20,439
-8,200
| -29% | -$62.4K |
|
|
BWAY
2739
Brainsway
BWAY
$575M
| $151K | ﹤0.01% |
+57,272
| New | +$179K |
|
|
ZTR
2740
Virtus Total Return Fund
ZTR
$337M
| $150K | ﹤0.01% |
+26,979
| New | +$144K |
|
2741
Antero Midstream
AM
$10.5B
| $149K | ﹤0.01% |
10,618
-56,082
| -84% | -$717K |
|
2742
Verrica Pharmaceuticals
VRCA
$85.2M
| $149K | ﹤0.01% |
+2,509
| New | +$139K |
|
2743
Babcock & Wilcox
BW
$1.18B
| $146K | ﹤0.01% |
129,448
-368,666
| -74% | -$456K |
|
2744
GeneDx Holdings
WGS
$2.62B
| $145K | ﹤0.01% |
15,870
+1,406
| +10% | +$8.44K |
|
|
AFMD
2745
DELISTED
Affimed
AFMD
| $145K | ﹤0.01% |
27,323
-35,837
| -57% | -$204K |
|
|
CTLP
2746
DELISTED
Cantaloupe
CTLP
| $145K | ﹤0.01% |
22,521
-1,136
| -5% | -$7.49K |
|
|
AGTI
2747
DELISTED
Agiliti Inc
AGTI
| $145K | ﹤0.01% |
+14,302
| New | +$120K |
|
2748
Verastem
VSTM
$644M
| $143K | ﹤0.01% |
12,082
-10,530
| -47% | -$122K |
|
2749
BlackRock Energy and Resources Trust
BGR
$436M
| $141K | ﹤0.01% |
+10,609
| New | +$132K |
|
2750
BlackRock Enhanced Global Dividend Trust
BOE
$693M
| $140K | ﹤0.01% |
+13,388
| New | +$136K |
|
Similar funds
John Overdeck's Q1 2024 Portfolio in Review
As of Q1 2024, John Overdeck held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
John Overdeck withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, John Overdeck opened a new position in Pfizer worth $234M.
- John Overdeck's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- John Overdeck added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- John Overdeck's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- John Overdeck fully exited Rivian in Q1 2024, selling an estimated $158M.
- John Overdeck's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- John Overdeck opened 408 new positions and closed 532 in Q1 2024.
- John Overdeck's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.